Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioVersys AG ( (CH:BIOV) ) has issued an update.
BioVersys AG has entered into a global research collaboration with Shionogi & Co., Ltd. to develop novel ansamycin leads from its BV500 program into clinical candidates for non-tuberculous mycobacteria (NTM) infections. This partnership allows BioVersys to receive CHF 5.0 million in upfront and research payments, with potential for up to CHF 479 million in milestones and royalties. The collaboration aims to expedite the development of BioVersys’ NTM asset, leveraging Shionogi’s expertise in infectious diseases, and is expected to benefit patients and stakeholders by advancing innovative treatments for significant unmet medical needs.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF62.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG is a clinical stage biopharmaceutical company based in Basel, Switzerland, focusing on the development of novel antibacterial products targeting multidrug-resistant bacteria. The company leverages its internal technology platforms, TRIC and Ansamycin Chemistry, to create treatments for serious infections and bacteria-related chronic inflammatory disorders. BioVersys is advancing programs for infections like Acinetobacter baumannii and tuberculosis, with collaborations including GlaxoSmithKline and the University of Lille.
Average Trading Volume: 1,097
For a thorough assessment of BIOV stock, go to TipRanks’ Stock Analysis page.